News

Back

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

March 1st 2022

BSCB Dev

IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses based in Germany, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s broad range of vector technologies. 

Read Pdf